Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Capital Expenditures (2016 - 2025)

Apyx Medical's Capital Expenditures history spans 15 years, with the latest figure at $275000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 12.24% year-over-year to $275000.0; the TTM value through Dec 2025 reached $1.1 million, up 54.29%, while the annual FY2025 figure was $1.1 million, 54.29% up from the prior year.
  • Capital Expenditures reached $275000.0 in Q4 2025 per APYX's latest filing, down from $519000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $519000.0 in Q3 2025 to a low of $29000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $205100.0, with a median of $181000.0 recorded in 2022.
  • The largest YoY upside for Capital Expenditures was 1788.89% in 2021 against a maximum downside of 69.15% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $332000.0 in 2021, then tumbled by 57.23% to $142000.0 in 2022, then plummeted by 34.51% to $93000.0 in 2023, then soared by 163.44% to $245000.0 in 2024, then rose by 12.24% to $275000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Capital Expenditures are $275000.0 (Q4 2025), $519000.0 (Q3 2025), and $265000.0 (Q2 2025).